Simple Summary A better understanding of the role of KRAS and its different mutations has
led to the development of specific small-molecule inhibitors able to target KRAS G12C, an …

Simple Summary KRAS gene mutations are among the most common oncogenic lesions in
NSCLC patients. For many years, they were considered “incurable”. This is now changing …

Anti-angiogenic therapy represents a promising strategy for non-small-cell lung cancer
(NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to the …

Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …

We developed multi-modality radiomic models by integrating information extracted from 18 F-
FDG PET and CT images using feature-and image-level fusions, toward improved prognosis …

Despite known histological, biological, and clinical differences between lung
adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known …

Objective Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung
cancers, but its pathogenesis has not been fully elucidated. Therefore, it is valuable to …

Lung cancer is the second most frequently diagnosed cancer type and responsible for the
highest number of cancer deaths worldwide. Lung adenocarcinoma (LUAD) and lung …

Intercellular communication plays an essential role in lung cancer (LC). One of the major
players in cell‐cell‐communication is small extracellular vesicles (sEV). SEV trigger various …

Lung cancer continues to be the leading cause of cancer-related death in the world, which is
classically subgrouped into two major histological types: Non-small cell lung cancer …